BOEHRINGER INGELHEIM
Boehringer
Ingelheim life sciences ' community – representing more than 50 % of its pipeline projects – and the company ’ s animal health business is now the second largest in the world , with more than 200 products for dogs , cats , horses , pigs , cattle and poultry .
To add to this , Boehringer Ingelheim is also investing € 35bn in health innovation to tackle non-communicable diseases , as well as an additional € 250mn in partnerships to combat emerging infectious diseases . Through its flagship initiative Making More Health , it has partnered with Ashoka , the largest global network of social entrepreneurs . To mitigate the environmental impact of its growing business , Boehringer Ingelheim has
“ WE WORK TO MAKE HUMANITY BETTER , RIGHT ? TO MAKE THE LIVES OF PEOPLE AND ANIMALS BETTER EVERY DAY ”
BRUNO RIZZUTI HEAD OF DATA MANAGEMENT , BOEHRINGER INGELHEIM committed to becoming carbon neutral in its operations and halving its resource footprint by 2030 .
Driving innovation across the enterprise with advanced technologies Boehringer Ingelheim is driving innovation across the enterprise and has focused on advanced technologies to discover new ways of introducing technology to core business processes . Big Data and analytics powered by AI allows the company to build new models and predictive tools that can have far-reaching impact on production processes , improving the quality , connectivity and availability of patient solutions .
70 January 2023